Market Overview

UPDATE: Swedbank Downgrades AstraZeneca to Sell; Margins Under Pressure

Share:
Related AZN
After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?
Price Bump From M&A Rumors Earns Acadia A Vetr Downgrade
AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink (Investor's Business Daily)

Swedbank downgraded AstraZeneca (NYSE: AZN) from Reduce to Sell.

Swedbank noted, "Later in March, AstraZeneca will stage its first CMD with a new strategy and a new leadership. It is already clear that this will involve committed investments to transform the pipeline's size and potential. Together with the top-line pressure, this should squeeze the short-term earnings. Upside should be revealed gradually after 2015."

AstraZeneca closed at $45.80 on Thursday.

Latest Ratings for AZN

DateFirmActionFromTo
Dec 2016Leerink SwannUpgradesMarket PerformOutperform
Sep 2016PiperJaffrayInitiates Coverage onOverweight
Sep 2016Exane BNP ParibasDowngradesOutperformNeutral

View More Analyst Ratings for AZN
View the Latest Analyst Ratings

Posted-In: SwedbankAnalyst Color Downgrades Analyst Ratings

 

Related Articles (AZN)

View Comments and Join the Discussion!